Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study

Supportive Care in Cancer

Volumn 18, Issue 6, 2010, Pages 691-698

  Atahan, Lale ^a   Yildiz, Ferah ^a   Cengiz, Mustafa ^a   Kaplan, Bunyamin ^b   Özkan, Metin ^b   Yazici, Gozde ^c   Gündoǧ, Mete ^b   Haydaroǧlu, Ayfer ^d   Korcum, Aylin F ^e   Şengöz, Meriç ^f   Dinçer, Maktav ^g   Akmansu, Müge ^h   Engin, Kayihan ^i,j   Hayran, Mutlu ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c MINISTRY OF HEALTH   (Turkey)

^d EGE UNIVERSITY   (Turkey)

^e AKDENIZ UNIVERSITY   (Turkey)

^f MARMARA UNIVERSITY   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h GAZI UNIVERSITY   (Turkey)

ⁱ ULUDAG UNIVERSITY   (Turkey)

^j Anadolu Saǧlik Merkezi ^*  (Turkey)

more..

Author keywords

Bone metastasis; Breast cancer; Radiotherapy; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SAFETY; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; WHOLE BODY SCINTISCANNING; BONE NEOPLASMS; BREAST NEOPLASMS; CONTROLLED STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; PAIN MEASUREMENT; PALLIATIVE THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PAIN MEASUREMENT; PALLIATIVE CARE; RADIOTHERAPY DOSAGE; KAPLAN-MEIER ESTIMATE;

EID: 77953621327     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0663-x     Document Type: Article

References (39)

1. Domchek SM, Younger J, Finkelstein DM, Seiden MW (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363-368. doi:10.1002/1097-0142 (20000715)89:2<363::AID-CNCR22>3.0.CO;2- 3
2. Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6:161-171. doi:10.1007/s11864-005-0023-0
3. Coleman RE (2001) Metastatic bone disease: clinical features, pathophsiology and treatment strategies. Cancer Treat Rev 27:165-176. doi:10.1053/ctrv.2000.0210 (Pubitemid 32452017)
4. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
5. Bates T (1992) A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23:217-221
6. Maher EJ (1992) The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer 28:706-710. doi:10.1016/S0959-8049(05)80131-5
7. Fleisch H (2002) Development of bisphophonates. Breast Cancer Res 4:30-34. doi:10.1186/bcr414 (Pubitemid 34097554)
8. Gnant M, Mlineritsch B, Schippinger W et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849. doi:10.1016/S1470-2045(08)70204-3
9. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057. doi:10.1200/JCO.2003.08.017 (Pubitemid 46606220)
10. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Easton D, Austin D, Palmer SG, Yarnold JR (1986) Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247-255. doi:10.1016/S0167-8140(86)80191-8
11. Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer 50:893-899. doi:10.1002/1097-0142(19820901)50:5<893::AID- CNCR2820500515>3.0.CO;2-Y (Pubitemid 12047122)
12. Madsen EL (1983) Painful bone metastases: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy× 6 versus 10 Gy×2. Int J Radiat Oncol Biol Phys 9:1775-1779
13. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M (2005) Randomized trial of short-versus long- course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 11:798-804
14. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594-605. doi:10.1016/S0360-3016(02) 04147-0 (Pubitemid 36170000)
15. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single-versus multipl-fraction radiotherapy in patients with painful bone metastases: cost-Utility analysis based on a randomized trial. J Natl Cancer Inst 95:222-229
16. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD (2003) Palliation of metastatic bone pain: single fraction versus multi- fraction radiotherapy-A systematic rewiev of randomized trials. Clin Oncol 15:345-352. doi:10.1016/S0936-6555(03)00113-4 (Pubitemid 37069647)
17. Crellin AM, Marks A, Maher EJ (1989) Why don't British radiotherapists give single fractions of radiotherapy for bone metastases. Clin Oncol 1:63-66. doi:10.1016/S0936-6555(89)80036-6
18. Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415. doi:10.1007/BF02555852
19. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl):2961-2978. doi:10.1002/1097-0142(20000615)88:12+<2961::AID- CNCR12>3.0.CO;2-L
20. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorptio in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242
21. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K (2002) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40-47. doi:10.1007/s002230010047 (Pubitemid 36934735)
22. Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796. doi:10.1210/en.141.12.4793 (Pubitemid 32055161)
23. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342. doi:10.1038/nature01658 (Pubitemid 40852708)
24. Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474
25. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 98:1735-1744. doi:10.1002/cncr.11701 (Pubitemid 37238631)
26. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43. doi:10.1002/cncr.11892 (Pubitemid 37553537)
27. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a Randomized, Placebo-Controlled Trial. J Clin Oncol 23:3314-3321. doi:10.1200/JCO.2005.05.116
28. Coleman RE, Rosen LS, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen B-L, Seaman JJ (2002) Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res Treat 76(suppl.):355
29. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphophonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468
30. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegrin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastases. Cancer Res 61:4432-4436
31. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S (1996) Biphophonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705. doi:10.1172/JCI118841
32. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Biphophonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894
33. Vogt U, Bielawski KP, Bosse U, Schlotter CM (2004) Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclo-phosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12:1109-1114
34. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134. doi:10.1054/bjoc.2001.1727 (Pubitemid 32448513)
35. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371. doi:10.1002/ijc.20602 (Pubitemid 40038702)
36. Magnetto S, Boissier S, Delmas PD, Clezardin P (1999) Additive antitumor activities of taxoids in combination with the biphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83:263-269. doi:10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0. CO;2-T (Pubitemid 29449107)
37. Ural AU, Avcu F, Candir M, Guden M, Ozcan MA (2006) In vitro synergistic effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52. doi:10.1186/bcr1543 (Pubitemid 44405299)
38. Arrington SA, Damron TA, Mann KA, Allen MJ (2008) Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 97:284-290. doi:10.1002/jso.20949 (Pubitemid 351312171)
39. Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:1468-1472. doi:10.1002/1097- 0142(19850401)5:<1468::AID-CNCR2820550708>3.0.CO;2-M